Trial reportThe Journal of clinical investigation2015
MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids.
Trial report in The Journal of clinical investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 1 synthesis or guideline pooled it, 244 citations in OpenAlex.
- Effects of rapid growth on fasting insulin and insulin resistance: a system review and meta-analysis.European journal of clinical nutrition · 2021Pooled it
- Unraveling the Time-Dependent Effects of Ethanol on Liver Disease: Insights From a Mice Model.Biotechnology and applied biochemistry · 2026Article
- Exosomal MicroRNAs as theranostic tools in type 2 diabetes and its complications: mechanistic insights and clinical implications.Diabetology & metabolic syndrome · 2026Review
- The Role of MicroRNAs in Mitochondrial Homeostasis and their Involvement in the Pathogenesis of Obesity and Metabolic Syndrome: A Focus on MicroRNAs.Current medicinal chemistry · 2026Review
- Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease.Frontiers in cell and developmental biology · 2026Article
- Article
- Characterization and biological health implications of microRNAs from human milk and infant formulas.NPJ science of food · 2025Review
- Review
- Pathological Glucose Levels Enhance Entry Factor Expression and Hepatic SARS-CoV-2 Infection.Journal of cellular and molecular medicine · 2025Article
- Circulating microRNAs as Potential Biomarkers of Overweight and Obesity in Adults: A Narrative Review.Genes · 2025Review
- Identifying insulin-responsive circRNAs in chicken pectoralis.BMC genomics · 2025Article
- Unlocking the Diagnostic and Therapeutic Potential of microRNA in Diabetes: A Bibliometric and Visualized Analysis (2003-2023).Journal of multidisciplinary healthcare · 2025Article
- Differential microRNA profiling of the Marshallese population in Arkansas reveals a higher association with chronic diseases.PloS one · 2025Article
- MicroRNA: A Novel Class of Potential Biomarkers and Therapeutic Target for Non-Alcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.MicroRNA (Shariqah, United Arab Emirates) · 2025Review
- Role of micrornas in the pathophysiology and diagnosis of metabolic dysfunction-associated steatotic liver disease: A bibliometric review.Hepatology forum · 2025Review
- Lipophagy and epigenetic alterations are related to metabolic dysfunction-associated steatotic liver disease progression in an experimental model.World journal of hepatology · 2024Article
- The Role of Hypothalamic Microglia in the Onset of Insulin Resistance and Type 2 Diabetes: A Neuro-Immune Perspective.International journal of molecular sciences · 2024Review
- MiR-26a Inhibits Porcine Adipogenesis by Regulating ACADM and ACSL1 Genes and Cell Cycle Progression.Animals : an open access journal from MDPI · 2024Article
- A predicted epithelial-to-mesenchymal transition-associated mRNA/miRNA axis contributes to the progression of diabetic liver disease.Scientific reports · 2024Article
- Multi-step regulation of microRNA expression and secretion into small extracellular vesicles by insulin.Cell reports · 2024Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Type 2 diabetes (T2D) is characterized by insulin resistance and increased hepatic glucose production, yet the molecular mechanisms underlying these abnormalities are poorly understood. MicroRNAs (miRs) are a class of small, noncoding RNAs that have been implicated in the regulation of human diseases, including T2D. miR-26a is known to play a critical role in tumorigenesis; however, its function in cellular metabolism remains unknown. Here, we determined that miR-26a regulates insulin signaling and metabolism of glucose and lipids. Compared with lean individuals, overweight humans had decreased expression of miR-26a in the liver. Moreover, miR-26 was downregulated in 2 obese mouse models compared with control animals. Global or liver-specific overexpression of miR-26a in mice fed a high-fat diet improved insulin sensitivity, decreased hepatic glucose production, and decreased fatty acid synthesis, thereby preventing obesity-induced metabolic complications. Conversely, silencing of endogenous miR-26a in conventional diet-fed mice impaired insulin sensitivity, enhanced glucose production, and increased fatty acid synthesis. miR-26a targeted several key regulators of hepatic metabolism and insulin signaling. These findings reveal miR-26a as a regulator of liver metabolism and suggest miR-26a should be further explored as a potential target for the treatment of T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.